Clinical Trial Update: A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Solbinsiran (LY3561774) in participants with severe hypertriglyceridemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertriglyceridemia

Drugs mentioned

• Solbinsiran (LY3561774)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Severe Hypertriglyceridemia | Phase 2 | Status: RECRUITING